Ashkenazi has been key to managing the windfall in revenue and wave of investor optimism from Eli Lilly's diabetes injection Mounjaro and obesity drug Zepbound.
Eli Lilly has more work it wants to do with the hard-won success from its weight loss and diabetes drugs, Zepbound and Mounjaro, outgoing CFO Anat Ashkenazi told CNBC.
"You have to be a really good student of the business and understand it inside and out and understand the industry," she told CNBC in an interview before her departure announcement. "Only when we understand the full system, can we navigate it well so that we bring value to it…That's my role as CFO."have both struggled to manufacture enough supply of their treatments to meet unprecedented demand, causing nationwide shortages of those drugs.
"As we start selling product and we get the revenue in and cash flow associated with that sale," the company wants to "funnel that cash flow back to the business to invest in those manufacturing facilities," she said.to match the pace of demand this year and maybe not even in 2025, Ashkenazi said at a conference in March. But the pharmaceutical giant has made encouraging progress so far.
Still, Ashkenazi said coverage of Zepbound by U.S. commercial insurers is improving, with about 67% commercial coverage as of April 1. Eli Lilly is working to build that access for the remainder of the patients, she noted.
Biotechnology Biotech And Pharmaceuticals Pharmaceuticals Health Care Industry Eli Lilly And Co Novo Nordisk A/S Alphabet Inc Business News
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Alphabet names Eli Lilly veteran Ashkenazi as CFOAlphabet names Eli Lilly veteran Ashkenazi as CFO
Read more »
Alphabet taps Eli Lilly's Anat Ashkenazi as new CFOThe new Google executive will replace Ruth Porat, who will become president and chief investment officer of the company after nearly a decade as CFO.
Read more »
FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Read more »
Eli Lilly's diabetes drug tirzepatide gets approval in ChinaEli Lilly's diabetes drug tirzepatide gets approval in China
Read more »
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulinsThe rivalry between Eli Lilly and Novo Nordisk extends beyond weight loss and diabetes drugs. Meanwhile, Uber has announced new features for caregivers.
Read more »
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulinsThe rivalry between Eli Lilly and Novo Nordisk extends beyond weight loss and diabetes drugs. Meanwhile, Uber has announced new features for caregivers.
Read more »